Research programme: anticancer therapeutics - JW Therapeutics/Lyell Immunopharma

Latest Information Update: 07 Dec 2020

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

10 Aug 2020 Anticancer therapeutics - JW Therapeutics/Lyell Immunopharma is available for licensing as of 10 Aug 2020
10 Aug 2020 JW Therapeutics and Lyell Immunopharma agree to co-develop t cell therapies for Solid tumours
10 Aug 2020 Early research in Solid tumours in China (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com